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To date, not much has been known regarding the role
of CD80 and CD86 molecules in signaling of B cells. The
CD28/CTLA4 ligands, CD80 (B7-1) and CD86 (B7-2), are
expressed on the surface of freshly isolated splenic B
cells, and their expression is up-regulated by lipopo-
lysaccharides. In the present study, we have investi-
gated whether signaling via CD80/CD86 could alter the
proliferation and immunoglobulin synthesis of B cells.
Splenic B cells were stimulated with lipopolysaccha-
rides in the presence of anti-B7-1 (16-10A1) and anti-B7-2
(GL1) monoclonal antibodies (mAbs). Exciting features
observed during the study were that cross-linking of
CD86 with GL1 enhanced the proliferation and produc-
tion of IgG1 and IgG2a isotypes. In contrast, anti-B7-1
(16-10A1) mAb could efficiently block the proliferation
and production of IgG1 and IgG2a. Furthermore, GL1
mAb could also induce the secretion of IgG isotypes
from B cell lymphomas. Importantly, 16-10A1 could re-
tard the growth of lymphomas and favored the up-reg-
ulation of pro-apoptotic molecules caspase-3, caspase-8,
Fas, FasL, Bak, and Bax and down-regulation of anti-
apoptotic molecule Bcl-x(L). In contrast, GL1 aug-
mented the level of anti-apoptotic molecules Bcl-w and
Bcl-x(L) and decreased the levels of pro-apoptotic mole-
cule caspase-8, thereby providing a novel insight into
the mechanism whereby triggering through CD80 and
CD86 could deliver regulatory signals. Thus, this study
is the first demonstration of a distinct signaling event
induced by CD80 and CD86 molecules in B cell lym-
phoma. Finally, the significance of the finding is that
CD80 provided negative signal for the proliferation and
IgG secretion of normal B cells and B cell lymphomas. In
contrast, CD86 encouraged the activity of B cells.
Evidence from a variety of studies has suggested that the B
cell contact with T helper cells is important for its optimal
activation and responsiveness to cytokines during Ig secretion
(1–3). Contact between B and T cells can be mediated by anti-
gen presentation, as well as antigen-independent cell interac-
tion by molecules known as adhesion (LFA-1, LFA-3, ICAM-1,
etc.) and costimulatory molecules (CD80, CD86, CD40, etc.)
(3–7). Signals from T cells induce two opposite fates in B cells:
clonal expansion of B cells that bind specifically to foreign
antigens and clonal deletion of equivalent B cells that bind
self-antigen. The role of costimulatory molecules is very well
established in the activation of T cells (3), but nothing has been
determined definitively about how these molecules operate in
the activation and differentiation of B cells (8–10).
The best defined co-stimulators to date are two structurally
related proteins, CD80 and CD86 (11–14). Both of these play a
major role in providing costimulation to T cells, leading to their
proliferation, cytokine production, and development of effector
functions. CD80 and CD86 could also serve as counter-recep-
tors that transduce distinct signal to the antigen-presenting
cells upon engagement by CD28 or CTLA-4. The intracellular
domains of CD80 and CD86 are quite distinct and could medi-
ate differential signal transduction. Such signaling could alter
the B cells’ ability to function as effector cells. The ability of the
B cells to deliver the costimulatory signal to T cells by B7
molecules is very well established (15–17). In contrast, whether
the engagement of CD80 and CD86 molecules by CD28 and
CTLA-4 affect the function of the B cells is very poorly docu-
mented (9, 10). Moreover, nothing is known precisely in the
case of B cell proliferation and differentiation by the engage-
ment of CD80 and CD86 molecules. However, there is indirect
evidence reported earlier that CD28-CTLA4/B7-signaling path-
ways may affect B cell responses and the regulation of immu-
noglobulin (Ig) synthesis (18–20). To compare the regulatory
role of CD80 (B7-1) and CD86 (B7-2) molecules in humoral
immune responses, B7-1/ and B7-2/ mice were generated
and profound deficits in both antigen-specific IgG1 (Th2-de-
pendent) and IgG2a (Th1-dependent) responses demonstrated
that B7 costimulation can influence IgG production in vivo (21).
However, the basis of this abnormal Ig production was contrib-
uted to the absence of Th1- or Th2-specific cytokines in B7-1/
2/ mice that regulate the IgG1 and IgG2a production.
Thus, the aim of our study was to evaluate for the first time
the role of CD80- and CD86-mediated signal transduction in
the costimulation of B cells. The results show that triggering
through CD80 specifically inhibits the proliferation and IgG
secretion by LPS1-stimulated B cells. By contrast, CD86 chiefly
augments the B cell activity. Further, the growth of B cell
lymphomas could also be retarded by CD80 cross-linking. Sig-
naling through CD80 inhibited the growth of the B cell lym-
phoma by up-regulating the expression of pro-apoptotic mole-
cules caspase-3, caspase-8, Fas, FasL, Bak, and Bax and down-
regulating the levels of anti-apoptotic molecule Bcl-x(L). In
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contrast, triggering through CD86 augmented the level of anti-
apoptotic molecules Bcl-w and Bcl-x(L) and decreased the lev-
els of caspase-8. Thus, the signals delivered by anti-B7-1 and
-B7-2 antibodies can differentially regulate the activity of B cell
and its lymphoma.
EXPERIMENTAL PROCEDURES
Animals
Female inbred BALB/c mice (8–10 weeks old) were obtained from the
National Institute of Immunology (New Delhi, India).
Antigens, Antibodies, Lymphokines, and Reagents
Fetal calf serum was purchased from Sera-Lab (Crawley Down,
United Kingdom), RPMI 1640 was from Invitrogen, L-glutamine and
streptomycin were from Serva (Heidelberg, Germany), and recombi-
nant IL-4 and IFN- were the products of Genzyme (Boston, MA). LPS
(from Salmonella typhosa), mIgG1, mIgG2a, and rabbit anti-rat FITC-
labeled Ab were procured from Sigma and goat anti-rat IgG F(ab)2 from
Jackson ImmunoResearch Laboratories (West Grove, PA). Anti-B7-1,
CD40, Fas-FITC, FasL-biotin mAbs were purchased from PharMingen
(San Diego, CA) and anti-B7-2 Ab was a gift from Dr. Vijay Kuchroo
(Boston, MA). Rabbit anti-caspase-3 (CPP32) antibody was purchased
from Santa Cruz Biotechnologies. The RPA kit was purchased from
PharMingen. Enhanced chemiluminescence kit (ECL) was a product of
Amersham Biosciences, Inc., and polyvinylidene difluoride membrane
was from Bio-Rad.
Cell Lines and Hybridomas
The cell lines and hybridomas used in this study, i.e. CRL 1704, TIB
208, HB 188, and HB 170, were procured from American Type Culture
Collection (ATCC; Rockville, MD).
Medium
Cells were cultured in RPMI 1640 medium supplemented with 10%
FCS, L-glutamine (2 mM), penicillin (50 g/ml), streptomycin (50 g/ml),
and 2-mercaptoethanol (0.05 mM).
Cell Preparation
B Cells—B cells were prepared as reported previously (2). Briefly, a
single cell suspension of BALB/c mice spleens was prepared in balanced
salt solution. The red blood cells were depleted by treatment with
hemolytic Gey’s solution. The adherent cells were removed by plating
on the plastic Petri plates (Nunc, Roskilde, Denmark) for 2 h at 37 °C
and 7% CO2. Nonadherent cells were incubated in nylon wool column
for 1 h at 37 °C in 7% CO2. The adherent cells eluted from the column
were treated sequentially on ice for 45 min each with a mixture of
anti-Mac2 and anti-Mac3 Abs and a mixture containing anti-Thy1,
L3T4, and CD8 Abs, followed by complement-mediated killing. The
purity of cells stained with anti-IgM Ab was over 95%, as analyzed by
FACS (Becton Dickinson, Mountain View, CA).
Expression of B7-1 and B7-2 on B Cells and WEHI-279—FACS
analysis was done as mentioned previously (2). Briefly, 1,000,000 B
cells (stimulated with 20 g/ml LPS for 48 h) and WEHI-279 cells were
incubated with the anti-B7-1, anti-B7-2, and CD40 Abs (1.0 g) diluted
in 100 l of PBS plus 2% BSA for 1 h at 4 °C. The cells were then
washed three times with PBS plus 2% BSA. Anti-rat FITC (1:135
dilution) was then added and the cells were further incubated for 1 h at
4 °C. The cells were washed five times with PBS and fixed in 1%
paraformaldehyde and analyzed by FACS for the expression of B7-1 and
B7-2 molecules. As a control for anti-B7-1 and anti-B7-2 Abs, the cells
were also incubated with RtIg.
The cells from each suspension were acquired on CellQuest software
for FACScan (Becton Dickinson). Debris in the cell suspension was
excluded from the analysis by suitable gating that allowed the collection
of data only from those light-scattering events (i.e. cells) of a size
consistent with B cells. The analysis for the mean fluorescence intensity
(MFI) was done on histograms, where abscissa and ordinate denote log
FITC fluorescence and relative cell count, respectively.
B Cell Proliferation—B cells activated with 20 g/ml lipopolysaccha-
ride (5  103 to 1  105 cells/well) were incubated with anti-B7-1 and
-B7-2 mAbs at a concentration of 0.01–1.0 g/ml in a total volume of 200
l of RPMI, 10% FCS at different (24–96 h) time intervals. The LPS-
activated B cells (1 105/well) were also cultured with optimum dose of
IFN- (10 units/ml) and IL-4 (100 units/ml) in the presence of different
concentration of anti-B7 mAbs. The suitable controls containing B cells,
LPS-activated B cells incubated with control RtIg, or B cells without
antibodies were also kept. The cells were incubated at 37 °C in a
humidified atmosphere containing 7% CO2. After the specified time
period, the cultures were pulsed with 0.5 Ci of [3H]thymidine/well.
After 16 h, the plates were harvested and incorporation of thymidine
was determined by using an automatic cell harvester (Skatron, Tranby,
Norway) and liquid scintillation counting.
IgG1 and IgG2a Isotypes
The cultures were set as mentioned in B cell proliferation assays. The
SNs were collected on day 6 from the experimental as well as control
wells and were analyzed for IgG1 and IgG2a by enzyme-linked immu-
nosorbent assay (2). Briefly, triplicate wells were coated overnight at
4 °C with 5 g/ml goat anti-mouse IgG1 and IgG2a Abs in carbonate-
bicarbonate buffer, pH 9.6. The unbound sites were blocked with 2%
BSA, and then log 6 dilutions of culture SNs were added for 2 h at 37 °C.
The plates were then incubated with rabbit anti-mouse IgG horseradish
peroxidase-labeled antibody at 37 °C for 2 h. The usual steps of wash-
ings with PBS-Tween 20 were carried at each step. The color developed
because of the substrate OPD was visualized at 492 nm. The concen-
tration of Abs is represented as nanograms/ml, as computed by using
standard mouse IgG1 and IgG2a isotypes.
Flow Cytometric Analysis of Intracellular IgG1 and IgG2a
Synthesis
The B cells (5 10 5/ml) stimulated with LPS (20 g/ml) were cultured
with anti-B7-1 and -B7-2 mAbs (1.0 g/ml) for 72 h. Four hours before
harvesting the cells, brefeldin A (10 g/ml) was added. The cells were
harvested and resuspended in PBS containing brefeldin A and fixed by
adding equal volume of 4% paraformaldehyde for 20 min. The cells were
incubated for 10 min in PBS/BSA/saponin to permeabilize the cells. The
cells were blocked with 0.5% rabbit sera and saponin and stained imme-
diately for intracellular expression of IgG1 and IgG2a using a modified
method described by Murphy et al. (22). The cells were incubated with
anti-IgG1-biotin and anti-IgG2a-biotin (2 g/ml) for 30 min and then with
avidin-FITC (1:1000 dilution). The usual steps of washings were followed
at each step using 1% BSA and 0.5% saponin. The last washing was done
in PBS/BSA without saponin to allow membrane closure. The samples
were analyzed by FACScan flow aptometer (Becton Dickinson). Results
were analyzed by CellQuest software.
The Proliferation of WEHI-279 Lymphoma and the Secretion of
IgG1 and IgG2a Isotypes
Different concentrations of WEHI-279 cells (5  102 to 5  103/well)
were cultured with anti-B7-1, B7-2, and CD40 mAbs (0.01–1.0 g/ml) in
a total volume of 200 l of RPMI, 10% FCS. The suitable controls
containing WEHI-279 cells cultured in the presence or absence of LPS,
control RtIg, or without antibodies were also kept. The cells were
incubated for 72 h, pulsed with 0.5 Ci of [3H]thymidine for another 4 h,
and then processed for -scintillation counting. Similar types of cul-
tures were also kept for 4–5 days, and SNs were harvested and ana-
lyzed for IgG1 and IgG2a secretion as mentioned above.
The Expression of Fas and FasL Demonstrated by FACScan on
the Surface of B Cells and WEHI-279 Lymphoma Stimulated
with Anti-B7-1, B7-2, and CD40 Abs
B cells (LPS-stimulated) and WEHI-279 cells were cultured for 48 h
with 1.0 g/ml anti-B7-1, B7-2, and CD40 Abs and control RtIg in 200
l of RPMI 1640 and 10% FCS. The cells were washed and labeled with
anti-Fas-FITC and anti-FasL-biotin/avidin-FITC. As mentioned above,
the expression was demonstrated by FACScan.
Demonstration of Apoptosis on B Cells and WEHI-279 Cells
Induced by Anti-B7-1 and -B7-2 Abs
Apoptosis was detected by utilizing the method developed by Nico-
letti (23). Briefly, B cells and WEHI-279 cells were stimulated with
anti-B7-1 and -B7-2 Abs (1.0 g/ml) for 48 h. The cells were further
incubated with anti-Fas Ab (1.0 g/ml) for a period of 14 h. The cells
harvested from the cultures were centrifuged; the cell pellet was fixed
in 0.5 ml of cold 70% ethanol at 4 °C for 1 h. The cells were centrifuged
again and resuspended in 0.5 ml of RNase (1.0 mg/ml) and incubated at
room temperature for 20 min. Finally, 30 l of propidium iodide (0.1
mg/ml) was added into each sample and incubated for another 10 min
in the dark at room temperature before cell cycle was analyzed by flow
cytometry. Apoptosis in the cells was analyzed by a FACScan with
cytomation, data acquisition, and software (lysis II) for red fluores-
cence. Initial identification of the cells was made with the help of
FSC/SSC plots. The apoptotic cells were selected on the basis of the
expression of higher SSC because of the condensation of the nuclear
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chromatin. The debris was excluded on the basis of its very low SSC and
FSC signals, and normal cells were gated and analyzed.
The Induction of the Expression of Pro-apoptotic and Anti-
apoptotic Molecules after Cross-linking CD80 and CD86
Molecules on WEHI-279 Cells
Multi-probe Ribonuclease Protection Assay—The WEHI-279 cells
were cultured with anti-CD80 Ab, anti-CD86 Ab, and RtIg Ab and
cross-linked with anti-RtIg Ab as mentioned for the proliferation assay.
Total RNA was extracted from WEHI-279 cells by the guanidinium
isothiocyanate-phenol-chloroform method using Trizol reagent (Invitro-
gen). The expression was determined using the RiboQuant multiprobe
RNase protection assay system (PharMingen) following the manufac-
turer’s instruction (24). Briefly, 5 g of total RNA was hybridized to
32P-labeled RNA probes overnight at 56 °C, followed by treatment with
RNase for 45 min at 30 °C. In each set we have included L32 (which
encodes a ribosomal protein) and glyceraldehyde-3-phosphate dehydro-
genase genes to serve as housekeeping gene controls. The samples were
submitted to electrophoresis through a 8 M urea, 5% polyacrylamide gel.
The probe lengths are greater than the “protected” fragment lengths;
this is because of the presence of flanking sequences. The resulting
resolved bands were imaged using a phosphorimager (Bio-Rad Molec-
ular Imager FX). The normalized quantity for each band was obtained
by dividing with L32 housekeeping gene control. The -fold activation
(increase or decrease) was calculated by dividing the value of normal-
ized quantity of the experimental samples with that of WEHI-279 cells
cultured with medium alone.
Western Blotting—WEHI-279 cells were incubated with anti-B7-1 Ab
or RtIg and cross-linked with anti-RtIg as mentioned for the prolifera-
tion assay. The experiment was done as mentioned previously (25, 26).
Briefly, after incubation, cells were washed twice with ice-cold PBS and
re-suspended in lysis buffer (1% Triton X-100, 0.32 M sucrose, 5 mM
EDTA, 1 mM phenylmethylsulfonyl fluoride, 1.0 g/ml aprotinin, 1.0
g/ml leupeptin, 2 mM dithiothreitol, 10 mM Tris-HCl, pH 8) for 5 min
at 4 °C followed by protein determination with BCA method (Pierce).
The protein (50 g) was resolved on 12% polyacrylamide gel and was
assayed by Western blotting using anti-caspase-3 Ab. The expression
levels were analyzed using NIH Image software.
RESULTS
Expression of CD80 and CD86 on B Cells and
WEHI-279 Cells
The FACScan revealed the presence of CD80 (MFI of 106.49)
and CD86 (MFI of 155.80) molecules on B cells incubated with
LPS for 48 h (Fig. 1a). We also evaluated the expression of
CD80, CD86, and CD40 molecules on the B cell lymphoma,
WEHI-279. WEHI-279 expressed CD80 (MFI of 190.09), CD86
(MFI of 111.51), and CD40 (MFI of 125.73) molecules (Fig. 1b).
The RtIg used as control for anti-B7-1 and -B7-2 mAbs failed to
show any significant shift in MFI.
Cross-linking of CD80 Inhibits but CD86 Increases the
Proliferation of LPS-activated B Cells
We next determined whether triggering of CD80 and CD86
molecules by their respective mAbs will affect the proliferation
and differentiation of LPS-activated B cells. The experiments
were performed with different concentrations of responder cells
and readout at different time points after stimulation. Surpris-
ingly, cross-linking of CD80 with anti-B7-1 mAb (16-10A1)
significantly inhibited the proliferation of different doses (5 
103 to 1 105 cells/well) of LPS stimulated B cells from as early
as 24 h of the cultures. The maximum decline (61.56%) in the
proliferation was observed when the B cells were cultured at
the concentration of 5  104 with 16-10A1 (1.0 g/ml) for 48 h
(Fig. 2A). It is worth to mention here that 16-10A1 was found to
be highly potent for a range of 5  103 to 1  105 cells at a
concentration of 1.0 g/ml in significantly down-regulating the
proliferation of B cells at any time period (24–96 h) of the
study. The response was observed in a dose-dependent manner.
Unlike anti-B7-1 mAb, signaling by anti-B7-2 mAb (GL1)
significantly enhanced the proliferation of LPS stimulated B
cells (Fig. 2B). There was gradual increase in the proliferation
of B cells, irrespective of cell concentration (5  103, 1  104,
5  104, and 1  105/well). The maximum and significantly
high proliferation (97.86%) was observed when 1  105 cells/
well were cultured with GL1 (1.0 g/ml) for 48 h. In contrast,
only 20.70% enhancement in the growth of B cells was observed
when the B cells were cultured for 96 h. On account of over-
proliferation and the death of the cells, the magnitude of pro-
liferation declined by the end of 96 h.
No spectacular difference in the activity of LPS-activated B
cell was noticed in the control cultures incubated with RtIg. B
cells incubated with medium and anti-B7-1 and -B7-2 mAbs did
not register any proliferation.
Regulation of the Secretion of IgG1 and IgG2a Isotypes by
B Cells Stimulated with Anti-B7-1 and -B7-2 mAbs
Anti-B7-1 mAb Inhibits whereas Anti-B7-2 mAb Augments
the Production of IgG Isotypes—We also evaluated the impact
of signaling through CD80 and CD86 on the secretion of IgG1
and IgG2a isotypes. We have chosen to measure IgG1 and
FIG. 1. B cells and WEHI-279 express B7-1 and B7-2 molecules.
The B cells (stimulated with LPS) (a) and WEHI-279 (b) were stained
with anti-B7 Abs and secondary anti-RtIg-FITC. In the case of WEHI-
279, the data depict probing of the cells with RtIg (A), anti-B7-1 Ab (B),
anti-B7-2 Ab (C), and anti-CD40 Ab (D). The expression of the mole-
cules on the cells was analyzed by FACS. The data shown in the
parentheses depict MFI. The figure is representative of at least three
experiments.
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IgG2a isotypes because of their production precisely by IL-4
and IFN-, respectively (17). Interestingly, anti-B7-1 mAb
down-regulated the production of both IgG1 and IgG2a (Fig.
3A). The concentration measured of IgG1 Ab was 114 ng/ml,
and that of IgG2a was 258 ng/ml, when the B cells were cul-
tured with LPS. There was significant decline in IgG1 from 114
to 44 ng/ml and in IgG2a from 258 to 44 ng/ml, when anti-B7-1
Ab was added into the cultures (Fig. 3A). More interestingly,
FIG. 2. Anti-B7-1 mAb down-regu-
late but anti-B7-2 mAb enhances the
proliferation of LPS-activated B
cells. Different concentration of B cells
was incubated with anti-B7-1 (A) and an-
ti-B7-2 Abs (B) and cross-linked with an-
ti-Rt Ab (2 g/ml). LPS (20 g/ml) was
also added, and the cultures were kept for
various time periods. After completion of
incubation, [3H]thymidine (0.5 Ci/well)
was added, the cells were harvested, and
radioactivity incorporated was counted
16 h later. RtIg was used as a control for
anti-B7-1 and -B7-2 Abs. B cells incu-
bated either with medium or anti-B7-1 Ab
or anti-B7-2 Ab or RtIg alone could not
generate more than 2000 cpm. The data
expressed as mean  S.D. are the repre-
sentative of at least three experiments.
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anti-B7-2 Ab critically increased the production of IgG1 (from
116 to 1750 ng/ml) and IgG2a (from 260 to 1944 ng/ml) iso-
types, when cocultured with LPS-stimulated B cells (Fig. 3B).
The inhibitory signals delivered by anti-B7-1 mAb (1.0 g/
ml) were powerful enough to down-regulate the secretion of
IgG1 and IgG2a induced by IL-4 (IgG1; from 610 to 518 ng/ml)
and IFN- (IgG2a; from 708 to 258 ng/ml), respectively (Fig.
3A). However, in the case of anti-B7-2 Ab (1.0 mg/ml) stimula-
tion, IL-4 (100 units/ml) and IFN- (10 units/ml) worked in a
synergistic fashion with the Ab and augmented the yield of
IgG1 (from 610 to 2188 ng/ml) and IgG2a (from 710 to 2482
ng/ml), respectively (Fig. 3B). Anti-IL-4 and IFN- Abs could
not block the production of IgG1 and IgG2a isotypes, respec-
tively, induced by anti-B7-2 mAb (data not shown). The mAbs
worked in a dose-dependent manner, and the maximum activ-
ity was attained at a concentration of 1.0 g/ml. The control
RtIg used in the cultures could not influence any change in B
cell activity.
Cross-linking of CD80 Down-regulates but Signaling
through CD86 Increases the Intracellular Expression of
IgG1 and IgG2a Isotypes
We also observed the distinct effect on the intracellular ex-
pression of IgG1 and IgG2a isotypes upon cross-linking CD80
and CD86 molecules with their respective mAbs. Similar re-
sults were seen as observed in the case of IgG secretion. Anti-
B7-1 mAb diminished, whereas anti-B7-2 mAb enhanced, the
intracellular exhibition of IgG1 and IgG2a-isotypes (Fig. 4).
CD80 Cross-linking Fails to Alter the Viability of B Cells
It was of concern for us whether the decrease in the prolif-
eration in B cells is a direct result of the death of the cells
induced by anti-B7-1 mAb stimulus or the inhibition in the
DNA synthesis. Therefore, we co-cultured LPS-stimulated B
cells with anti-B7-1 mAb and then monitored the viability of
cells by propidium iodide staining. It was ascertained that
anti-B7-1 mAb signaling did not alter the viability of the cells
(Fig. 5). No change in the expression of Fas and FasL was also
observed on B cells (data not shown).
Effect of Cross-linking of CD80, CD86, and CD40
Molecules on B Cell Lymphoma
Inhibition of the Proliferation of WEHI-279 by Anti-B7-1 and
CD40 Abs—Because the CD40 molecule has differential effect
on normal B cells and B cell lymphomas (27), we evaluated the
signaling capacity of CD80, CD86, and CD40 molecules in the
proliferation of WEHI-279 B cell lymphoma (Fig. 6). Interest-
ingly, anti-B7-1 and CD40 mAbs but not anti-B7-2 mAb could
significantly down-regulate the growth of WEHI-279 cells. The
dose of 1.0 g/ml anti-B7-1 mAb was highly potent in inhibiting
the proliferation of 500 and 5000 cells up to 43 and 29%,
respectively (Fig. 6, A and B). Similarly, the extent of anti-
CD40 mAb mediated inhibition was comparable with the effect
induced by anti-B7-1 mAb. It has also been reported previously
that anti-CD40 mAb renders WEHI-279 cells sensitive for Fas-
mediated killing (14). However, for the first time we have
FIG. 3. Anti-B7-1 Ab inhibits but anti-B7-2 Ab augments the
secretion of IgG1 and IgG2a isotypes by LPS stimulated B cells.
B cells (1  105/well) were incubated at 4 °C for 1 h with different
concentrations of anti-B7-1 Ab (A) and anti-B7-2 Ab (B) and LPS (20
g/ml), IL-4 (100 units/ml), and IFN- (10 units/ml). Anti-B7-1 Ab and
anti-B7-2 Ab were also present throughout the culture period. The cells
were incubated for 5–6 days, the supernatants were collected from
triplicate wells of control and experimental cultures, and IgG1 and
IgG2a were monitored by enzyme-linked immunosorbent assay. B cells
cultured with anti-B7-1 Ab in the absence of LPS could not generate Ab
response. The data (shown as nanograms/ml) are representative of at
least three similar experiments.
FIG. 4. Anti-B7-1 declines whereas anti-B7-2 enhances the in-
tracellular expression of IgG1 and IgG2a isotypes. The culture
conditions were same as those mentioned in Fig. 3. After cross-linking
B cells with antibodies to B7-1 and B7-2 and culturing with LPS,
intracellular staining was done using biotinylated anti-IgG1 and IgG2a
Abs and avidin-FITC (for details, see “Experimental Procedures”). The
analysis was done by FACScan. The figure is representative of at least
three experiments.
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demonstrated that anti-CD40 and anti-B7-1 mAbs show syn-
ergistic effect. Both the Abs, when added into the cultures,
inhibited the proliferation of WEHI-279 by 83 and 48% for the
two doses of the cells used in the experiments, respectively
(Fig. 6, A and B). The control cultures containing RtIg did not
induce any significant change in the growth of the cells.
Induction of the Secretion of IgG1 and IgG2a Isotypes by
Anti-B7-2 mAb-stimulated WEHI-279 Cells—Because anti-
B7-1 and -B7-2 mAbs could regulate the proliferative response
in B cells and WEHI-279 lymphoma and the differentiation
events in B cells, we were therefore curious to know whether
these antibodies could exert any impact on the secretion of
IgG1 and IgG2a by WEHI-279 cells. Accordingly, we monitored
the secretion of IgG1 and IgG2a isotypes, in the cultures of
WEHI-279, stimulated with antibodies to CD80 (B7-1), CD86
(B7-2), and CD40 molecules. WEHI-279 cells cultured with
medium alone or with LPS failed to show detectable level of
IgG-isotypes. Most surprisingly, anti-B7-2 mAb could signifi-
cantly induce WEHI-279 cells to secrete IgG1 and IgG2a (Fig.
7). However, anti-B7-1 and CD40 mAbs completely failed to
stimulate WEHI-279 cells to produce IgG isotypes. Similar
effects were also observed in the case of A20 lymphoma (data
not shown). The control cultures comprising WEHI-279 cells
and RtIg could not induce any change.
Cross-linking of CD80 and CD40 but Not CD86 Induces
the Expression of Fas and FasL on WEHI-279
Because anti-B7-1 and CD40 mAbs exerted decline in the
growth of WEHI-279, it became essential for us to monitor the
cause of this response. We therefore did flow cytometry to
explore the possibility of the expression of Fas and FasL on
WEHI-279 cells incubated with anti-B7-1, B7-2, and CD40 Abs
(Fig. 8). Importantly, anti-B7-1 and CD40 mAbs but not anti-
B7-2 mAb could successfully augment the expression of Fas
and FasL on WEHI-279 cells (Fig. 8, a and b). The control
cultures involving RtIg did not display any change in Fas and
FasL expression.
Cross-linking of CD80 Induces WEHI-279 Cells to
Undergo Apoptosis
We finally analyzed the functional activity of Fas and FasL
induced on the surface of WEHI-279 cells by propidium iodide
FIG. 5. Cross-linking of B7-1 do not induce any change in the
viability of B cells. B cells were incubated with LPS (A), control RtIg
(B), anti-B7-1 Ab (C), and anti-B7-2 Ab (D) for 48 h and then with
anti-Fas Ab for 14 h. The cells were stained with propidium iodide and
apoptosis was monitored by FACS analysis (for details, see “Experimen-
tal Procedures”). The data shown in parentheses represent the percent-
age of the positive apoptotic cells. The figure is representative of at least
three experiments.
FIG. 6. Anti-B7-1 and CD40 Abs arrest the growth of WEHI-279
lymphomas. Anti-B7-1, anti-B7-2, and CD40 Abs (1.0 g/ml) were
incubated with 5  102 cells/well (A) and 5  103 cells/well (B) of
WEHI-279 lymphoma. The cultures were kept for 72 h, and the prolif-
eration was monitored at the last 6 h of cultures by [3H]thymidine
incorporation. WEHI-279 cultured with medium alone showed 43,890
3485 cpm and 21,7177  7532 cpm for 5  102 cells/well and 5  103
cells/well, respectively. In control cultures, RtIg did not register any
detectable change. Results expressed are the mean  S.D. of three
experiments.
FIG. 7. Signals by anti-B7-2 Ab but not anti-B7-1 and CD40 Abs
induces the production of IgG1 and IgG2a isotypes by WEHI-279
cells. WEHI-279 (5  103 cells/well) was cultured with different con-
centrations of anti-B7-1 (0.01–1.0 g/ml), anti-B7-2 (0.01–1.0 g/ml),
and CD40 (0.01–1.0 g/ml) Abs; after 5 days, the SNs from the control
and experimental wells were collected and IgG1 and IgG2a were meas-
ured as mentioned in legend to Fig. 3. WEHI-279 cells cultured with
medium alone or with control RtIg could not evoke the secretion of the
isotypes. The data are representative of three similar experiments.
Regulation of B Cells by CD80 and CD86 Molecules 7771
 by guest on D
ecem
ber 17, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
staining. Interestingly, WEHI-279 cells incubated with anti-
Fas mAb in the absence of CD80 cross-linking showed a MFI of
5.80 (Fig. 9A). However, cross-linking of CD80 into the cultures
exhibited 8.00-fold increase (MFI of 46.40) in the number of
cells undergoing apoptosis (Fig. 9B). CD86 cross-linking could
induce only marginal change (Fig. 9C). We also observed the
DNA-ladder formation when CD80 was cross-linked (data not
shown).
Cross-linking of CD80 Enhances the Expression of
Pro-apoptotic Molecules, whereas CD86 Up-regulates
the Level of Anti-apoptotic Molecules
Finally, we tested the involvement of the apoptosis-regula-
tory molecules representative from several classes of proteins,
namely caspase-3, caspase-8, Fas, FasL, Fas-associated death
domain, Fas-associated phosphatase, Fas-associated factor,
TNF-related apoptosis-inducing ligand (Fas2L), tumor necrosis
factor (TNF) receptor (p55), TNF receptor-associated death
domain, receptor inhibitory protein, Bak, Bax, Bad, Bcl-w,
Bfl-1, Bcl-xL, and Bcl-2 (Figs. 10–12). The expression of the
molecules was analyzed by flow cytometry (Fig. 8), ribonucle-
ase protection assay (RPA) (Figs. 10 and 11), and Western
blotting (Fig. 12). Anti-CD80 Ab mediated signaling signifi-
FIG. 8. Anti-B7-1 and CD40 Abs but not anti-B7-2 Ab induces
the expression of Fas and FasL on WEHI-279 lymphomas. The
cells were incubated for 48 h with medium (A), anti-B7-1 (B), B7-2 (C),
or CD40 (D) Abs and control RtIg (E). The expression of Fas (a) and
FasL (b) was evaluated by staining with their respective Abs and
analyzed by FACS. The data shown in the parentheses depict MFI. The
figure is representative of at least three experiments.
FIG. 9. Cross-linking by anti-B7-1 Ab induces apoptosis of
WEHI-279 lymphoma. The cells were incubated with medium (A),
anti-B7-1 Ab (B), or anti-B7-2 Ab (C) for 48 h and then with anti-Fas Ab
for 14 h. The cells were stained with propidium iodide, and apoptosis
was monitored by FACS. The data shown in parentheses represent
percentage of positive apoptotic cells. The figure is representative of at
least two experiments.
FIG. 10. Signaling through CD80 enhances the expression of
pro-apoptotic molecules. A multiprobe ribonuclease protection assay
was performed to detect the expression of apoptosis-regulatory mole-
cules in WEHI-279 cells. Five micrograms of RNA was analyzed in each
lane. Lane A, probe; lanes B–E, cells cultured with medium (B), RtIg
(C), anti-CD80 Ab (D), or anti-CD86 Ab (E). Glyceraldehyde-3-phos-
phate dehydrogenase and L32 were used to serve as housekeeping gene
controls. The results shown are representative of two experiments (A).
Histogram for the normalized quantity for each band was obtained by
dividing with L32 housekeeping gene control. The -fold activation was
calculated by dividing the value of normalized quantity of the experi-
ment with WEHI-279 cells cultured with medium alone. The results
expressed as mean  S.D. are obtained from two experiments (B).
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cantly and reproducibly up-regulated the levels of caspase-3,
caspase-8, Fas, FasL, Bak, and Bax (Figs. 10–12). Maximum
increase was observed in the case of Bax (8.16-fold) followed by
Fas (8.0-fold), Bak (4.95-fold), FasL (4.6), and caspase-8 (4.16)
(Figs. 10 (a and b) and 11 (a and b)). Further, stimulation
through CD80 molecule could also decrease the expression of
anti-apoptotic molecules Bcl-x(L) (4.95). The expression of
other pro-apoptotic (namely Fas-associated death domain, Fas-
associatedphosphatase,Fas-associated factor,TNF-relatedapo-
ptosis-inducing ligand, TNF receptor, TNF receptor-associated
death domain, receptor inhibitory protein, and Bad) and anti-
apoptotic (Bcl-w, Bfl-1, Bcl-2) molecules remained unaltered. In
contrast, CD86 mediated signaling significantly enhanced the
expression of anti-apoptotic molecules Bcl-w (4.23-fold) and
Bcl-xL (3.36-fold) (Fig. 11, a and b). Potent decrease in the level
of pro-apoptotic marker caspase-8 (4.04-fold) and marginal
down-regulation of Bak was also noticed.
DISCUSSION
An array of costimulatory molecules, e.g. ICAM-1, LFA-1,
VCAM-1, HSA, CD40, and B7 (1–5), are expressed on the
surface of B cells. Their role has gained considerable signifi-
cance in the activation of T cells, but very little is known in
connection with the activation of B cells (7, 8). The exact mech-
anism of sequence of signals provided by different costimula-
tory molecules in the stimulation and inhibition of B cells is
largely unknown.
In the present study, we have attempted to analyze the
distinct role of CD80 and CD86 costimulatory molecules in the
activation and differentiation of B cells. The following five
major findings have emerged from this study. 1) Cross-linking
by anti-B7-1 mAb (16-10A1) inhibited the proliferation and
differentiation of B cells; 2) anti-B7-2 mAb (GL1) promoted the
growth and differentiation of B cells; 3) anti-B7-1 and CD40
mAbs acted synergistically and declined the growth of B cell
lymphomas; 4) induction of secretion of IgG isotypes by WEHI-
279 cells was triggered with anti-B7-2 mAb; 5) anti-B7-1 mAbs
induced apoptosis in B cell lymphoma by enhancing the expres-
sion of caspase-3, caspase-8, Fas, FasL, Bak, and Bax and
decreasing the expression of anti-apoptotic molecules Bcl-x(L).
Our findings suggest that CD80 and CD86 costimulatory
molecules are responsible for delivering the signals essential
for the inhibition and expansion of B cells, respectively. Hence
it may be inferred that anti-B7-1 mAb provides a type of inhib-
itory signals to B cells similar to those delivered by CTLA-4 to
T cells (28). Different studies have suggested a role of CD28
and CTLA-4 in the regulation of Ig synthesis. Defective pro-
duction of switched Ig isotypes is seen both in mice treated with
soluble CTLA-4 and in mice transgenic for CTLA-4 (16, 29, 30).
CD28-deficient mice have reduced basal levels of IgG1 and
IgG2a and diminished immunoglobulin class switching (15).
Further, in vivo blocking of CD86 with anti-B7-2 mAb has
shown the arrest of the germinal center formation and resulted
in the reduction in primary antibody production (31). These
results are in line with our observations about the negative
signal transduction through CD80. To best of our knowledge,
this is the first report regarding the role of CD80 and CD86
FIG. 11. Signaling through CD86 enhances the expression of
anti-apoptotic molecules. A multiprobe ribonuclease protection as-
say was performed to detect the expression of apoptosis-regulatory
molecules in WEHI-279 cells. Five micrograms of RNA was analyzed in
each track. Lane A, probe; lanes B–E, cells cultured with medium (B),
RtIg (C), anti-CD80 Ab (D), or anti-CD86 Ab (E). Glyceraldehyde-3-
phosphate dehydrogenase and L32 were used to serve as housekeeping
gene controls. The results shown are the representative of two assays
(A). Histogram for the normalized quantity for each band was obtained
by diving with L32 housekeeping gene control. The -fold increase or
decrease was calculated by dividing the value of normalized quantity of
test samples with that of WEHI-279 cells cultured with medium alone.
The results expressed as mean  S.D. are obtained from two experi-
ments (B).
FIG. 12. Signaling through CD80 up-regulates the expression
of caspase-3. The cell extracts obtained from the WEHI-279 cells
cultured with medium (lane 1), RtIg (lane 2), and anti-CD80 Ab (lane 3)
was resolved on 12% polyacrylamide gel and was assayed by Western
blotting using anti-caspase-3 Ab (A). The histogram represents the
density of expression levels (arbitrary units) obtained by analyzing with
NIH Image software (B). The results shown are obtained from a single
experiment.
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molecules in influencing the B cell activity. In the present
study, we used a T-independent system and preferred to ligate
CD80 and CD86 with their respective mAbs to rule out the
possibility of interference of other accessory signals when B cell
interacts with T cell. As compared with CD28, CTLA-4 mole-
cule binds to CD80 with 20-fold higher avidity. It is also known
that signaling through CTLA-4 can function to suppress the
production of cytokines produced by T-helper cells that helps
the differentiation of B cells (32). CD86 is also known to bind to
CTLA-4 but with low affinity as compared with CD80. Simi-
larly, interaction of CD86 with CD28 has high affinity, and
delivers positive signals for T cell activation. Further, the prop-
erty of CD80 in delivering inhibitory signals may also be re-
lated to its slower off-rate for CTLA-4 binding, thereby provid-
ing ample time to deliver signaling events necessary for
restraining B cells from being activated (33).
The kinetics of rapid and high level of expression of CD86 in
early immune responses and the delayed expression of CD80 on
antigen presenting cells can be viewed as necessary activation
and inhibitory signals, respectively, delivered by these mole-
cules during the immune response (34).
Another important conclusion that can be drawn from our
data is that the IL-4- and IFN--induced secretion of IgG1 and
IgG2a, respectively, could be inhibited by anti-B7-1 Ab. IL-4
and IFN- acted synergistically with anti-B7-2 Ab and aug-
mented the production of IgG1 and IgG2a, respectively. Inter-
estingly, IL-4 could inhibit the secretion of IgG2a induced by
anti-B7-2 Ab but IFN- failed to obstruct the secretion of IgG1,
even though the latter has antagonistic property for IL-4. At
present, this activity of IL-4 and IFN- is difficult to explain.
However, it has been reported that IL-4 induces the secretion of
IgG1 by LPS-activated B cells but inhibits the formation of
IgG2a. In contrast, IFN- promotes the yield of IgG2a and
down-regulated the production of IgG1 (17).
In the present study, B7-1 and B7-2 served as counter-recep-
tors that transduced distinct signals to B cells upon engage-
ment with their respective antibodies. The differential signal-
ing effect may also be because of the dissimilarity in the
structure and, in particular, the nature of their cytoplasmic tail
(18). Especially B7-2 has a significant cytoplasmic tail, which
has a markedly different cytosolic domain from that of B7-1
and contains a tyrosine residue. Further, unlike B7-1, the
cytoplasmic domain of B7-2 contains three potential sites for
phosphorylation by protein kinase C (35–37). The structure of
B7-1 has a short cytoplasmic tail and does not predict intrinsic
tyrosine kinase activity; therefore, if B7-1 must transduce sig-
nals, specific tyrosine kinases must associate with the receptor
(38, 39). Earlier studies have suggested the transmembrane
signaling through B7/BB1 expressed on T lymphocytes (40).
Finally, it has been observed recently that the two regions in
CD80 cytoplasmic tail regulate T cell costimulation and CD80
redistribution. A 30-kDa phosphoprotein has been found to be
associated with the cytoplasmic tail of CD80 after cell activa-
tion, suggesting it may play a role in CD80 function (41). In line
with these observations, it has been demonstrated that CD80
and CD86 can mediate differential signal transduction, and
such signaling could distinctly regulate the B cell’s function as
an effector cell (7, 8, 19, 20).
Our experiments also demonstrate that the augmentation
or inhibition of B cell activity is a concerted effect of the
signaling by B7 molecules and cytokines. It was still of con-
cern that this activity may be because of survival/death sta-
tus only, and all changes in levels of Ig production and
costimulation simply lead to further enhancement or de-
crease in B cell survival. To address the issue, the experi-
ments were carried to study the role of anti-B7 Abs in affect-
ing B cell viability and trans-membrane signaling. The
triggering of B cells by anti-B7-1 or anti-B7-2 mAbs could not
cast any impact on the viability of normal B cells, as
evidenced by propidium iodide staining. Further, CD80 cross-
linking could not induce Fas or FasL expression on the sur-
face of B cells. Furthermore, we established categorically that
this event of B cell activity is because of signaling, as evi-
denced by rapid alteration in phosphorylation of tyrosine
residues, and not because of overproliferation/death by CD86
cross-linking (data not shown). This was further substanti-
ated by differential regulation of intracellular expression of
IgG1 and IgG2a by CD80 and CD86 ligation. These experi-
ments very clearly demonstrate that isotype production is not
a mere function of proliferation/survival of B cell, rather it is
because of delivery of stimulatory or inhibitory signals
through CD80 and CD86 costimulatory molecules,
respectively.
To further provide weight to our findings of the regulatory
capacity of anti-B7-1 and -B7-2 Abs in the activation of B cells,
we utilized B cell lymphomas, WEHI-279, which express CD80,
CD86, and CD40 molecules. More surprisingly, anti-CD80 and
CD40 Abs could significantly arrest the proliferation of WEHI-
279. Thus it may be concluded that the signaling via CD80 and
CD40 molecules may be responsible for inhibiting the growth of
B cell lymphomas. In contrast, costimulation through CD86
may help lymphomas to proliferate and secrete antibodies that
may help lymphomas to evade immune surveillance. Further,
triggering through CD80 and CD40 may help the regression of
the lymphomas in the early stages. Although signaling through
CD80 retards the growth of B cell lymphomas by inducing the
expression of Fas and FasL and in turn induces apoptosis, it
fails to induce Fas and FasL or apoptosis in normal B cells. At
present, it is difficult to explain why ligation of B7-1 with
anti-B7-1 has a differential effect on normal versus tumor B
cells. This could be because of the involvement of the distinct
domains of CD80 in normal B cells and B lymphomas. More-
over, this observation is in agreement with the fact that, in the
case of CD40 molecule, antibodies to CD40 stimulate normal
B-lymphocytes but inhibit proliferation of B cell lymphoma
(27). Further, binding of CD40 ligand to CD40 on a murine B
lymphoma induces B7-1 and inhibits cell growth (12, 14). The
dual nature of signaling events has also been reported in the
case of BCR triggering. It has been shown that BCR signaling
induces apoptosis in germinal center B cells but not in periph-
eral B cells. Mature germinal center B cells can re-acquire
sensitivity to BCR-induced cell death following CD40 ligation.
In contrast, neither virgin nor memory B cells become suscep-
tible to antigen receptor-triggered apoptosis upon CD40 stim-
ulation (42).
Apart from demonstrating the expression of Fas and FasL by
FACScan and their involvement in inducing apoptosis, we also
monitored by ribonuclease protection assay the involvement of
CD80 and CD86 molecules in the regulation of the activation of
several pro- and anti-apoptotic molecules in WEHI-279 B cell
lymphoma. We have observed that signaling through CD80
molecule augmented the levels of pro-apoptotic molecules, i.e.
caspase-3, caspase-8, Fas, FasL, Bak, and Bax. This suggests
that CD80 signaling induces apoptosis in WEHI-279 via mech-
anism involving pro-apoptotic molecules caspase-3, caspase-8,
Fas, FasL, Bak, and Bax, thus rendering WEHI-279 cells more
vulnerable to apoptosis and therefore restricting the progres-
sion of the lymphoma. The T cell co-stimulatory molecule
CD28, which has a high and low binding affinity for CD86 and
CD80, respectively, promotes T cell survival by up-regulating
Bcl-x(L) and down-regulating FasL expression (43). Based on
these results and our findings, it may be postulated that there
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may exist a probability that, when CD28 is ligated with CD86,
it may deliver a protective signal necessary for the clonal ex-
pansion of B cells. In contrast to this, when CTLA-4 gets
engaged with CD80, it may deliver a lethal signal responsible
for controlling the clonal expansion of B cell and B cell lympho-
mas. Further, overexpression of caspases is sufficient to cause
apoptosis and Bax have been correlated with disease progres-
sion and shorter survival of B cell chronic lymphocytic leuke-
mia patients (44, 45). In contrast, signaling through CD86
increased the expression of anti-apoptotic molecules Bcl-w and
Bcl-x(L). Thus, there may be a possibility that ligation of B7-2
on WEHI-279 may promote their survival by increasing the
expression of anti-apoptotic proteins Bcl-w and Bcl-x(L). It has
also been reported earlier that increased expression of Bcl-x(L)
but not Bcl-2 could prevent the apoptosis in B cell lymphoma
WEHI-231 (46). Further, it has been reported that signaling
through CD40 up-regulated Bcl-x(L) and Bfl-1 and protected B
cell lymphoma from apoptosis (47).
Recent studies have highlighted the lack of costimulatory
molecules as a predominant reason for the inefficient tumor
rejection (13, 14, 48). Moreover, if the lymphomas express
CD80, signaling through this molecule may impede their
growth by inducing the expression of pro-apoptotic and down-
regulating the levels of anti-apoptotic molecules and thereby
facilitating apoptosis (49, 50). It is important to mention here
that CD80-mediated delivery of inhibitory signals may not only
be responsible for apoptosis of CD80-bearing tumor cells, but
may also be responsible in the regulation of immune responses
and maintaining self-tolerance in B cells. Thus, in the case of
tumors, ligation of B7-1 by anti-CD80 Ab may also deliver
effective anti-tumor immunity.
In conclusion, we report here that selective inhibition of B
cell proliferation and differentiation via CD80 signaling may be
viewed as a novel strategy to restrict the undesired stimulation
of B cell and progression of B cell lymphomas. The triggering
through B7-2 may play a crucial role in the activation of B cells.
This observation may therefore explain why there is the exist-
ence of both the isomers on a single cell. Taken together with
the data from others, these observations allow us to propose a
sequential positive and negative feedback model between B
and T cells. The predominance of the signals transduced
through CD28 and CTLA-4 govern the outcome of a T cell
immune response. As the CD80 and CD86 have been found to
have differences in their ability to bind CD28 and CTLA-4, the
predominant engagement of CD86 with CD28 leads to prolif-
eration of T cells, whereas stronger avidity of CTLA-4 with
CD80 delivers a down-regulatory signal for T cell responses
(29). On the other hand, our results show that stimulation
through CD80 and CD86 can modulate the humoral response
by transducing positive and negative signals in B cells and may
control the progression of B cell lymphomas.
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